Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ 49095397 · 1 trial · 1 indication
FEV1 is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. A positive change from baseline in FEV1 indicates improvement in lung function.
| Arm | Type | Description |
|---|---|---|
| JNJ 49095397 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JNJ 49095397 | DRUG | JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks. |
| Placebo | DRUG | Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks. |
Inclusion Criteria: * Men and women of non-child-bearing potential, Global Initiative for Chronic Obstructive Lung Disease (GOLD 2 or 3), forced expiratory volume in one second (FEV1) greater than or equal to 40 less than 80 percent predicted, FEV1/ forced vital capacity (FVC) ratio less than 0.7 *...
JNJ 49095397 is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is administered via inhalation and is intended for patients with moderate to severe COPD. The drug is currently in clinical development and has not been approved by regulatory authorities.
JNJ 49095397 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical trials to evaluate the drug's effectiveness and safety in patients with Chronic Obstructive Pulmonary Disease.
JNJ 49095397 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study involving 211 participants with moderate to severe Chronic Obstructive Pulmonary Disease. The drug remains investigational and is not yet approved.
JNJ 49095397 has been studied in one completed Phase 2 clinical trial registered as NCT01867762. This trial evaluated the effectiveness and safety of inhaled JNJ 49095397 (also known as RV568) in patients with moderate to severe Chronic Obstructive Pulmonary Disease. The study enrolled 211 participants across multiple countries.
Yes, JNJ 49095397 is also known as RV568. In the clinical trial NCT01867762, the drug is referred to as inhaled JNJ 49095397 (RV568). This alternative name is used in the study title and may appear in scientific literature and other references.